kabutan

AnGes, Inc.(4563) Summary

4563
TSE Growth
AnGes, Inc.
60
JPY
-2
(-3.23%)
Dec 12, 3:30 pm JST
0.38
USD
Dec 12, 1:30 am EST
Result
PTS
outside of trading hours
60.9
Dec 12, 11:38 pm JST
Summary Chart Historical News Financial Result
PER
PBR
5.64
Yield
ー%
Margin Trading Ratio
8.26
Stock Price
Dec 12, 2025
Opening Dec 12, 9:00 am
61 JPY 0.39 USD
Previous Close Dec 11
62 JPY 0.39 USD
High Dec 12, 9:02 am
62 JPY 0.39 USD
Low Dec 12, 10:00 am
60 JPY 0.38 USD
Volume
3,799,600
Trading Value
0.23B JPY 1.48M USD
VWAP
60.64 JPY 0.39 USD
Minimum Trading Value
6,000 JPY 38 USD
Market Cap
0.02T JPY 0.15B USD
Number of Trades
816
Liquidity & Number of Trades
As of Dec 12, 2025
Liquidity
Slightly High
1-Year Average
696
1-Year High Aug 12, 2025
5,987
Margin Trading
Date Short Interest Long Margin Positions Ratio
Dec 5, 2025 1,318,900 34,182,900 25.92
Nov 28, 2025 1,318,900 36,928,100 28.00
Nov 21, 2025 1,318,900 38,060,400 28.86
Nov 14, 2025 1,342,000 38,904,000 28.99
Nov 7, 2025 1,334,900 40,336,200 30.22
Company Profile
AnGes, Inc. is a biotech venture founded by an Osaka University professor, developing gene therapies and other pharmaceuticals. The company also sells treatments for intractable diseases.
Sector
Pharmaceuticals
AnGes, Inc. is a biotech venture originating from Osaka University Medical School, focusing on the development and sale of pharmaceuticals, particularly gene therapies. The company also provides contract testing services, primarily for rare genetic disease screening. Its subsidiary, EmendoBio Inc., possesses advanced genome editing technologies and is engaged in research and development of new treatments using genome editing products. In 2019, AnGes obtained conditional and time-limited manufacturing and marketing approval for "Collategene," the world's first plasmid DNA-based gene therapy product. The company has entered into an exclusive sales rights agreement with Mitsubishi Tanabe Pharma Corporation for the Japanese market, and has begun sales, recording product sales revenue.